CLR Berlin, celebrating its 100th anniversary this year, prides itself in its unique approach when it comes to the development of its active ingredients. For CLR, every NPD project starts with the following realization: cosmetic active ingredients are there for the benefit of the consumer. This implies understanding the consumers’ real needs and concerns in detail.
A current example of a product based on CLR’s approach is SkinCharge CLR™, which has been launched at in-cosmetics Global this year. This product addresses skin aging in totally new ways. Most people spend more time behind a screen, a computer screen, a tablet or mobile phone, than they spend sleeping.
A Relevant New Way of Looking at Skin Aging
Consumers understand that there are many negative aspects to the vast amount of screentime they have. They see this as a concern, but a concern they are not able to do much about. Screentime is simply part of daily life. Everybody is aware of eyes drying out when looking at a screen for a long time, or the impact it has on the quality of sleep. Consumers understand that their daily use of screens has negative impacts on their body and skin in a holistic way. They are beyond accepting that blue light from screens directly impacts their skin. At best, this is only part of the bigger picture.
The concerns of the consumer are real and relevant. There is a clear correlation between the amount of screentime people have and skin aging features. These can be linked through digital eye strain and the reduced quality of sleep, both of which are described to have an important negative impact on skin, which leads to the acceleration of skin aging. In CLR’s studies using AI, correlations between the hours people spend on a screen and skin aging features could be identified. For example, the AI-generated parameter “eye age” showed a clearly higher value for those people with a lot of screentime versus those with lower screentime. Other skin aging parameters, determined with a cutometer or AEVA-HE, also showed similar results.
SkinCharge CLR™: Addressing a True Consumer Need
SkinCharge CLR™ (proposed INCI: Vicia Faba Oligopeptides) is obtained from a careful extraction and a subsequent hydrolysis of the proteins from the beans of Vicia faba. In vitro and ex vivo studies with SkinCharge CLR™ showed that “drained” skin cells were enabled to produce higher amounts of collagens, hyaluronic acid and elastin. At the same time, it was shown that SkinCharge CLR™ could reduce the expression of destructive proteases.
Figure 1 - Treatment with SkinCharge CLR™ reduces eye age significantly and largely compensates for increased screen-time.Courtesy of CLR
In in vivo studies, the treatment with SkinCharge CLR™ showed a plethora of anti-aging, pro-longevity benefits for people with a lot of screentime. Eye age was reduced, virtually to the level of the eye age of people with a low screentime (see Figure 1). In addition, cheek fine lines, crow’s feet wrinkle and eye bags were also reduced significantly. Skin firmness and elasticity were increased. All, for people with elevated screen-time.
Figure 2 - Treatment with SkinCharge CLR™ improves skin comfort over 14 days and outperforms placebo.Courtesy of CLR
In addition, a placebo-controlled 14-day study with people who spend at least seven hours per day in front of screens was conducted. Interestingly, at the start of the study, for both groups of volunteers, the average skin feel was described as “tense.” After 14 days, the treatment of skin with an emulsion containing SkinCharge CLR™ had led to clearly increased skin comfort, significantly outperforming the placebo (see Figure 2).
Disclaimer:
The above paid-for content was produced by and posted on behalf of the Sponsor. Content provided is generated solely by the Sponsor or its affiliates, and it is the Sponsor’s responsibility for the accuracy, completeness and validity of all information included. Perfumer & Flavorist takes steps to ensure that you will not confuse sponsored content with content produced by Perfumer & Flavorist and governed by its editorial policy.
